How many GH Research share options at $12.3200 does Julie Ryan hold?

Julie Ryan holds share options over 50,487 GH Research ordinary shares at an exercise price of $12.3200 per share. These options expire on June 4, 2029 and, according to the footnote, are fully vested and exercisable as of the information provided.

Are Julie Ryan’s GH Research share options fully vested?

One option grant is described as fully vested and exercisable, covering 50,487 shares at $12.3200. The other grants vest 25% on specified dates, with remaining options vesting in equal monthly installments over three years, so those positions are subject to ongoing vesting over time.

GH Research (GHRS) VP, Finance reports multiple option grants

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

GH Research PLC VP, Finance Julie Ryan filed an initial statement of ownership showing multiple share option awards over ordinary shares. The holdings include options over 50,487 shares at an exercise price of $12.3200 per share expiring on June 4, 2029, and three additional grants over 17,500, 150,000, and 30,000 shares at an exercise price of $0.0250 per share with expirations on April 27, 2030, November 25, 2031, and May 16, 2032. Footnotes state one grant is fully vested and exercisable, while others vest 25% on specified dates with the remaining portions vesting in equal monthly installments over three years.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Ryan Julie

Role VP, Finance

Type	Security	Shares	Price	Value
holding	Share Options (Right to Buy)	--	--	--
holding	Share Options (Right to Buy)	--	--	--
holding	Share Options (Right to Buy)	--	--	--
holding	Share Options (Right to Buy)	--	--	--

Holdings After Transaction: Share Options (Right to Buy) — 50,487 shares (Direct)

Footnotes (1)

The share options are fully vested and exercisable. The share options vested as to 25% on April 27, 2024, and the remaining share options vest in equal monthly installments for three years thereafter. The share options vested as to 25% on November 25, 2025, and the remaining share options vest in equal monthly installments for three years thereafter. The share options vest as to 25% on May 16, 2026, and the remaining share options vest in equal monthly installments for three years thereafter.

Key Figures

Options at $12.3200: 50,487 shares at $12.3200 Options at $0.0250 (2020 grant): 17,500 shares at $0.0250 Options at $0.0250 (2021 grant): 150,000 shares at $0.0250 +3 more

6 metrics

Options at $12.3200 50,487 shares at $12.3200 Share options over ordinary shares expiring June 4, 2029

Options at $0.0250 (2020 grant) 17,500 shares at $0.0250 Share options expiring April 27, 2030

Options at $0.0250 (2021 grant) 150,000 shares at $0.0250 Share options expiring November 25, 2031

Options at $0.0250 (2022 grant) 30,000 shares at $0.0250 Share options expiring May 16, 2032

Fully vested grant One option grant fully vested Footnote states the share options are fully vested and exercisable

Standard vesting pattern 25% initial, remainder over 3 years Footnotes describe 25% vesting then equal monthly vesting for three years

Key Terms

Share Options (Right to Buy), Ordinary Shares, fully vested and exercisable, vest in equal monthly installments

4 terms

Ordinary Shares financial

"underlying_security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

fully vested and exercisable financial

"The share options are fully vested and exercisable."

vest in equal monthly installments financial

"the remaining share options vest in equal monthly installments for three years thereafter."

Understanding Insider Trading Forms →

04/02/2026 - 05:32 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ryan Julie

(Last)

(First)

(Middle)

C/O GH RESEARCH PLC, JOSHUA DAWSON HOUSE

DAWSON STREET

(Street)

DUBLIN

D02 RY95

(City)

(State)

(Zip)

IRELAND

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
GH Research PLC [ GHRS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	VP, Finance

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Share Options (Right to Buy)	⁽¹⁾	06/04/2029	Ordinary Shares	50,487	$12.32	D
Share Options (Right to Buy)	⁽²⁾	04/27/2030	Ordinary Shares	17,500	$0.025	D
Share Options (Right to Buy)	⁽³⁾	11/25/2031	Ordinary Shares	150,000	$0.025	D
Share Options (Right to Buy)	⁽⁴⁾	05/16/2032	Ordinary Shares	30,000	$0.025	D

Explanation of Responses:

1. The share options are fully vested and exercisable.

2. The share options vested as to 25% on April 27, 2024, and the remaining share options vest in equal monthly installments for three years thereafter.

3. The share options vested as to 25% on November 25, 2025, and the remaining share options vest in equal monthly installments for three years thereafter.

4. The share options vest as to 25% on May 16, 2026, and the remaining share options vest in equal monthly installments for three years thereafter.

	/s/ Julie Ryan	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does the GH Research (GHRS) Form 3 filing by Julie Ryan show?

The filing shows VP, Finance Julie Ryan’s existing share option holdings in GH Research PLC. It lists several option grants over ordinary shares with specific exercise prices, expiration dates, and vesting schedules, rather than reporting any new purchases or sales of stock.

What low-priced GH Research (GHRS) options are reported in this Form 3?

The filing reports three grants of share options with a $0.0250 exercise price over 17,500, 150,000, and 30,000 ordinary shares. These grants have expirations on April 27, 2030, November 25, 2031, and May 16, 2032, and each follows a 25% initial vesting and three-year monthly vesting schedule.

Does the GH Research Form 3 indicate any insider buying or selling?

The Form 3 data provided reflects holdings and remaining derivative positions, not explicit buy or sell transactions. Transaction codes are unspecified, and the summary counts show no recorded buys, sells, exercises, gifts, or tax withholdings, only holding entries for existing share options.